DSIP

DSIP

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide studied for its potential roles in sleep architecture, modulation of the hypothalamic-pituitary-adrenal (HPA) stress axis, and influence on pain signaling pathways, and is often grouped with sleep- and cognition-adjacent research peptides. Licensed practitioners who want to buy DSIP can contact Medical Spa Rx’s professional support team for guidance on sourcing from qualified suppliers and for access to supporting documentation, including purity information. Browse this page to learn more about DSIP and its research applications through the overview and FAQ sections below.

DSIP: Legal Status, Research Classification & Nootropic Identity

DSIP (Delta Sleep-Inducing Peptide) is an endogenous nonapeptide first isolated in 1977 by Schoenenberger-Monnier and colleagues from rabbit cerebral venous blood [5]. It is primarily investigated for its effects on sleep dysregulation, HPA axis modulation, and brain health protocols due to its apparent influence on sleep signaling, stress response, and neuroendocrine regulation. DSIP is commonly discussed in sleep- and cognition-adjacent peptide research protocols, although its cognitive effects are largely indirect, mediated through sleep restoration and stress reduction rather than direct receptor-level enhancement.

Much of the available human literature originates from Soviet-era and Eastern European clinical investigations conducted between the 1970s and 1990s, often involving small samples of 7–16 patients [2], [3], [4]. While these studies generated research interest, many would not meet modern standards for trial design, randomization, or reporting transparency. All findings from this evidence base should be interpreted with explicit awareness of these methodological limitations.

Regulatory Status (as of mid 2026)

• United States: Not FDA-approved for any clinical indication. As of April 22, 2026, DSIP was removed from FDA Category 2 and is now under review by the Pharmacy Compounding Advisory Committee (PCAC), scheduled for July 24, 2026. If approved, it would become available via licensed compounding pharmacies. Current status remains “research compound only” pending that decision.
• Australia: Not TGA-approved; availability through compounding channels is limited and subject to regulatory interpretation
• WADA: Not currently listed on the WADA Prohibited List; athletes should independently verify current status before use, as classification of emerging compounds can change

How DSIP Works: Sleep, HPA Axis & Pain Modulation

DSIP may influence several pathways involved in sleep regulation, stress response, and pain perception. Importantly, no DSIP-specific receptor has been identified, and neither the DSIP gene nor the DSIP protein has been isolated [1]. A 2006 review by Kovalzon and Strekalova described DSIP as “a still unresolved riddle,” noting that the hypothesis regarding DSIP as a sleep factor is “extremely poorly documented and still weak” [1]. All mechanistic claims below should be understood within that context.

Sleep architecture (Mixed/conflicting human evidence)

• DSIP may modulate GABAergic and serotonergic signaling within hypothalamic sleep-regulating centers, but findings on sleep effects are mixed and inconsistent across studies [1], [2], [3]
• A double-blind crossover study (Monti et al., 1987) found no significant increase in slow-wave sleep stages 3–4 following IV administration of 25 nmol/kg; only stage 2 sleep increased, and the investigators concluded that sleep improvement was “of little clinical significance” [3]
• A 1992 double-blind parallel-groups study of 16 chronic insomniacs (Bes et al.) found improved sleep efficiency with DSIP versus placebo, but concluded that “short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit” [2]
• Overall, evidence for effects on sleep architecture is heterogeneous and rarely replicated in contemporary research [1]

HPA axis modulation (Preclinical / early human data)

• May suppress corticotropin-releasing hormone (CRH) activity and reduce cortisol responses, potentially relevant to stress-related sleep disruption and circadian instability
• Direct clinical evidence remains limited

Pain signaling and opioid receptor interaction (Single small open-label pilot study — 1984; hypothesis-generating only)

• Some evidence suggests interaction with opioid-peptidergic systems, though this remains speculative [1]
• A 1984 open-label study by Kaeser involving 7 patients with severe insomnia reported sleep normalization in 6 of 7 participants following a series of 10 DSIP injections, with improved daytime mood and performance also noted [4]
• This is a single small open-label study with no control group and no replication; it is hypothesis-generating only and cannot support clinical conclusions

Circadian rhythm support (Preclinical/preliminary)

• Circadian effects remain preliminary and not well established; indirect interactions with pineal gland function and melatonin signaling have been proposed but not confirmed in controlled human trials
• Rapid eye movement sleep architecture may also be influenced, though findings are preliminary

Antioxidant and neuroprotective activity (Preclinical animal models only)

• Free-radical scavenging and potential neuroprotective effects have been observed in laboratory and animal research
• Should not be interpreted as confirmed clinical outcomes in humans

DSIP Peptide Benefits, Dosage & Administration

Reported benefits, dosing strategies, and administration methods remain key considerations when evaluating the DSIP peptide for sleep, stress, and neuroendocrine research. All claims carry evidence-tier qualifiers and should not be interpreted as clinically established outcomes.

Reported DSIP Benefits

• Sleep quality (Mixed evidence): Early studies showed reduced sleep latency and increased stage 2 sleep, but double-blind trials produced conflicting results [2], [3]. Monti et al. (1987) found no significant increase in slow-wave sleep and concluded that the improvement was of little clinical significance [3]. Bes et al. (1992) found improved sleep efficiency in chronic insomniacs but concluded short-term treatment is unlikely to offer major therapeutic benefit [2]. Evidence is heterogeneous and not well replicated.
• HPA axis regulation (Preclinical/early human): May support stress resilience and reduce stress-related sleep disruption through cortisol modulation; evidence remains limited
• Insomnia and sleep restoration (Single small open-label study — hypothesis-generating only): Kaeser (1984) reported sleep normalization in 6 of 7 patients with severe insomnia following a series of DSIP injections [4]. Findings are insufficient to support clinical conclusions and require validation through modern controlled trials.
• Indirect cognitive support (Practitioner-reported / extrapolated): Restorative sleep may support memory consolidation and cognitive performance; these effects are secondary to sleep regulation, not direct nootropic activity

DSIP Dosage and Administration

(Practitioner-reported / research-extrapolated; no validated human protocol exists)

• Historical clinical dosing: Controlled trials used 25 nmol/kg IV (approximately 21 mcg/kg body weight) administered before sleep [3]; Kaeser (1984) used a series of 10 injections [4]
• Current practitioner-reported protocols: 100–500 mcg subcutaneously, administered near natural sleep onset; this extrapolation from historical dosing lacks controlled human trial validation
• DSIP nasal spray is available via compounding as a non-injectable alternative; comparative bioavailability versus subcutaneous administration remains poorly characterized
• Cycle length: 1–4 weeks; anecdotal reports suggest tachyphylaxis with prolonged continuous use, leading practitioners to favor shorter cycles
• Reconstitution: bacteriostatic water; store at 2–8°C; protect from direct light

DSIP Side Effects & Safety Profile

Available safety data on the DSIP peptide remain limited, and the absence of extensive adverse-event reporting should not be interpreted as confirmation of safety. Most human evidence involves small samples from early investigations [2], [3], [4].

• Injection site reactions: Mild redness, swelling, or irritation at the subcutaneous injection site; generally transient and consistent with subcutaneous peptide protocols
• Transient hypotension: Reported in some early studies; additional monitoring is appropriate for individuals with cardiovascular vulnerabilities or those using prescription stimulants concurrently
• DSIP-like immunoreactivity at sleep transition: Plasma DSIP-like levels naturally decline at the transition from wakefulness to sleep, raising the possibility that DSIP is induced by sleep mechanisms rather than driving sleep itself [1]. This complicates the interpretation of therapeutic effects and warrants consideration when evaluating research findings.
• Long-term safety limitations: Human evidence is limited to small early studies with significant methodological limitations [2], [3], [4]. Long-term effects of repeated administration remain unknown and require contemporary clinical investigation.

DSIP vs. Selank

DSIP and Selank are both discussed within brain and neuroactive peptide research, but their primary mechanisms differ considerably. DSIP has been studied for possible effects on sleep architecture and HPA axis activity through GABAergic and serotonergic pathways, with any cognitive relevance arising indirectly from improved sleep and reduced allostatic load [1]. Selank, by contrast, acts through enkephalinase inhibition, GABAergic modulation, and BDNF upregulation; it has stronger evidence of direct anxiolytic effects, whereas DSIP’s cognitive effects remain indirect and sleep-mediated.

Practitioners may favor DSIP for sleep-first presentations where stress-driven cortisol dysregulation is the primary driver of cognitive dysfunction or insomnia. Selank is more appropriate where direct anxiolytic support or cognitive enhancement is the primary objective, independent of sleep architecture. When both sleep dysregulation and anxiety are present simultaneously, some practitioners discuss a combination rationale, though this remains practitioner-reported and research-extrapolated. Researchers who choose to buy Selank for comparative protocol work will find that its direct GABAergic and BDNF-mediated mechanisms provide a useful contrast to DSIP’s neuroendocrine-driven approach.

DSIP vs. Epithalon

DSIP and Epithalon both intersect with sleep and circadian health, but they target distinct physiological layers. DSIP addresses acute-to-subacute sleep dysregulation and HPA axis modulation through neuroendocrine signaling, making it most relevant to short-term interventions for stress-related insomnia [2], [3]. Epithalon is associated with telomerase activation, cellular longevity research, and regulation of pineal gland function through epigenetic mechanisms; it carries more robust longitudinal data from animal models on circadian regulation, whereas DSIP’s circadian effects remain primarily preclinical and mechanistically unconfirmed [1].

DSIP is generally the more relevant choice when near-term sleep restoration or active HPA axis intervention is the goal. Epithalon is more commonly explored in longevity-focused protocols and age-related circadian decline, where long-term epigenetic and regenerative effects are the primary interest. Researchers who buy Epithalon for comparative protocol work will find its telomerase-mediated mechanism and longevity research context provide a distinct reference point alongside DSIP’s neuroendocrine sleep focus.

Where Can Practitioners Buy DSIP Online?

DSIP is a research-grade compound available for purchase by qualified professionals only and is not intended for personal, therapeutic, or clinical use. Practitioners looking to order DSIP from a verified research-grade supplier should source only from vendors who can provide verifiable purity documentation, LOT number traceability, and a certificate of analysis for each batch. These standards are particularly important when buying online, where supplier transparency and manufacturing quality vary widely.

Medical Spa Rx’s professional support team offers sourcing guidance and documentation support to help licensed professionals identify qualified suppliers and evaluate wholesale buying options. Practitioners are encouraged to contact Medical Spa Rx’s professional support team directly for guidance on supplier standards, documentation requirements, and research-grade sourcing considerations when looking to buy DSIP wholesale.

FAQs

1. What is the DSIP peptide, and what is it used for?

DSIP, or Delta Sleep-Inducing Peptide, is an endogenous nonapeptide first isolated in 1977 by Schoenenberger-Monnier and colleagues from rabbit cerebral venous blood [5]. It is often grouped with sleep- and cognition-adjacent research peptides and is primarily investigated for sleep dysregulation, HPA axis modulation, and indirect support for cognitive health. DSIP is not FDA-approved and remains classified as a research compound, currently under PCAC review as of June 2026.

2. How does DSIP work — what is the mechanism of action?

Current evidence suggests that DSIP may modulate GABAergic and serotonergic signaling, but no specific DSIP receptor has been identified, and the peptide’s gene and protein have not been isolated [1]. A 2006 review by Kovalzon and Strekalova described DSIP as “a still unresolved riddle,” noting that the hypothesis regarding it as a sleep factor is extremely poorly documented [1]. Most mechanistic evidence derives from preclinical research and early human investigations with acknowledged methodological limitations.

3. What is the DSIP dosage — nasal spray vs. injection?

Controlled trials used 25 nmol/kg IV administered before sleep [3]. Current practitioner-reported protocols extrapolate to 100–500 mcg subcutaneously near bedtime, though this lacks controlled human trial validation. DSIP nasal spray is available via compounding as a non-injectable alternative, with limited comparative bioavailability data. All dosing should be considered research-extrapolated rather than clinically validated.

4. Is DSIP a nootropic peptide?

DSIP is often grouped with sleep- and cognition-adjacent research peptides rather than classified as a nootropic in any established scientific sense. Any cognitive relevance appears to arise indirectly through improved restorative sleep architecture and reduced physiological stress [1], [2]. This distinguishes it from compounds such as Selank, where direct anxiolytic and neuroplasticity mechanisms are more centrally involved.

5. How does DSIP compare to Selank and Epithalon?

DSIP has been studied for possible effects on sleep architecture and HPA axis modulation, though its mechanism remains poorly characterized [1]. Selank has stronger evidence for direct anxiolytic effects through enkephalinase inhibition and BDNF upregulation. Epithalon has more robust longitudinal animal model data on telomerase activation and circadian regulation. Each occupies a distinct mechanistic niche within sleep and neuroactive peptide research.

6. Is DSIP legal, and what is its safety profile?

As of June 2026, DSIP is not FDA-approved for any indication and remains under PCAC review, with a decision scheduled for July 24, 2026. It is not TGA-approved in Australia and is not currently on the WADA Prohibited List, though athletes should verify independently. Available evidence suggests generally favorable short-term tolerability [2], [3], [4], but long-term safety data remain insufficient. Most human evidence involves small samples with significant methodological limitations.

Sources

1. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303–309. doi:10.1111/j.1471-4159.2006.03693.x
2. Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193–197. doi:10.1159/000118919
3. Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res. 1987;7(2):105–110. PMID: 3583493
4. Kaeser HE. A clinical trial with DSIP. Eur Neurol. 1984;23(5):386–388. doi:10.1159/000115717 
5. Monnier M, Dudler L, Gächter R, Maier PF, Tobler HJ, Schoenenberger GA. The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide. Experientia. 1977;33(4):548–552. doi:10.1007/BF01922266

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.